Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 targeting strategies for achondroplasia.

Expert reviews in molecular medicine - 19 Jan 2012

Laederich Melanie B, Horton William A

Abstract excerpt

Mutations that exaggerate signalling of the receptor tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) give rise to achondroplasia, the most common form of dwarfism in humans. Here we review the clinical features, genetic aspects and molecular pathogenesis of achondroplasia and examine several therapeutic strategies designed to target the mutant receptor or its signalling pathways, including the use of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Achondroplasia
Share to Antibodies
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to RNA Interference

Share to Signal Transduction

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 22559284
DOI: 10.1017/erm.2012.4

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 targeting strategies for achondroplasia.PMID 22559284Read ↗

Novel therapeutic approaches for the treatment of achondroplasia.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor-3 as a Therapeutic Target for Achondroplasia - Genetic Short Limbed DwarfismSemantic proximity Read ↗

Achondroplasia: from genotype to phenotype.Semantic proximity Read ↗

Achondroplasia: pathogenesis and implications for future treatment.Semantic proximity Read ↗

Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasiaSemantic proximity Read ↗

Expanding horizons of achondroplasia treatment: current options and future developments.Semantic proximity Read ↗

Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.Semantic proximity Read ↗

International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia.Semantic proximity Read ↗

A novel homozygous mutation in FGFR3 causes tall stature, severe lateral tibial deviation, scoliosis, hearing impairment, camptodactyly, and arachnodactyly.Semantic proximity Read ↗

Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in MiceSemantic proximity Read ↗

Clinical Manifestations and Outcomes of 20 Korean Hypochondroplasia Patients with the FGFR3 N540K variant.Semantic proximity Read ↗

Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.